Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).
Reference facts
- Also known as
- Giapreza
- Category
- Neuropeptide & Other
- Mechanism of action
- Activates AT1 receptor (vasoconstriction, aldosterone release, sodium retention) and AT2 receptor (counter-regulatory).
- Targets
- AT1R, AT2R
- Indications under research or approved
- Septic / vasodilatory shock (Giapreza)
- Regulatory status (reference entry)
- FDA-approved (Giapreza 2017)
- Half-life
- ~15–30 seconds (native); 4 minutes for Giapreza infusion-corrected
- Sequence
- DRVYIHPF
- Sequence notes
- Octapeptide; cleaved from Angiotensin I by ACE.
- Molecular weight (Da)
- 1046
- Originator / sponsor
- La Jolla Pharmaceutical (Innoviva)
- First reported
- 1957
Primary References
Explore research articles about Angiotensin II
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.